RESOURCES

World Parkinson’s Day 2025: Advancing Parkinson’s Research with Cutting-Edge Mouse Models

April 11th marks World Parkinson’s Day, honoring James Parkinson, the pioneering physician who first systematically described the disease carrying his namesake. Parkinson’s disease (PD) is a progressive neurodegenerative disorder affecting millions worldwide, primarily impairing motor functions and often accompanied by cognitive decline. As the second most common neurodegenerative disease globally, its prevalence is projected to double by 2050, reaching more than 25 million patients. This growth underscores the urgent need for breakthroughs in understanding and treating PD.

Overcoming Obesity: Challenges Facing Weight Loss Drugs and the Promise of Combination Therapies

Mouse Models Bring Hope for Rare Disease Research

Featured on the Cover of Cell Metabolism! Publication on Cancer Cachexia Supported by GemPharmatech’s Mouse Models

Cancer cachexia, also known as “wasting syndrome,” is a common and serious complication in cancer patients. It is characterized by weight loss, reduced appetite, skeletal muscle atrophy, and fat degradation, significantly affecting the quality of life and increasing the risk of death. Currently, there are no effective treatments, and traditional nutritional support only partially alleviates symptoms. Therefore, in-depth research into its pathogenesis is especially important. GemPharmatech’s mouse models were recently cited in a December publication titled, "Disrupted methionine cycle triggers muscle atrophy in cancer cachexia through epigenetic regulation of REDD1" featured in Cell Metabolism. Read below to learn about this disease and how our models were used in the research.

Accelerating TCE Drug Development with Humanized Mouse Models

T-cell engagers (TCEs) are innovative bispecific antibodies designed to bind simultaneously to tumor-associated antigens (TAAs) and the CD3 receptor on T-cells. Several TCE drugs have already been approved, with seven bispecific antibodies targeting indications such as multiple myeloma and diffuse large B-cell lymphoma (DLBCL), focusing on markers like BCMA, GPRC5D, CD20, and CD19. In the realm of solid tumors, two TCE bispecific antibodies have received approval: Tebentafusp (Immunocore, January 2022, targeting CD3×GP100) and Tarlatamab (Amgen, May 2024, targeting CD3×DLL3). The accelerated approval of Tarlatamab has spurred increased interest in TCE bispecific antibodies for drug development in the solid tumor space. However, significant unmet clinical needs remain, especially for TCE bispecific antibodies targeting solid tumors.

To address this gap, GemPharmatech has established a comprehensive preclinical pharmacology and efficacy evaluation platform, offering a range of in vivo tumor models to support the development of TCE-based therapies.

Mouse Models for Studying Anti-PD-1 Resistance

Immune checkpoint inhibitors targeting PD-1/PD-L1 have revolutionized cancer treatment, offering broad-spectrum efficacy, prolonged durability, and relatively low toxicity[1]. Despite these advancements, the response rates in many cancers remain disappointing, often below 30%[2]. A significant proportion of patients experience partial responses or worse — eventually developing resistance leading to disease progression. These challenges highlight the urgent need for developing novel therapies to overcome anti-PD-1 resistance. This blog will explore how GemPharmatech has developed its own models of anti-PD-1 resistance.

New Publications on the MAPK Signaling Cascade Using GemPharmatech Mice

New Publication on Humanized Mouse Tumor Models

Mouse models to unlock the secrets of aging